THLD Trims Workforce, Sky Is Falling For SKBI, NERV On Track, CATB Moving Ahead

(RTTNews) - Catabasis Pharmaceuticals Inc. (CATB) has completed enrolment in Part A of its phase 1/2 trial of CAT-1004 for the treatment of Duchenne muscular dystrophy.

The company expects to report safety, tolerability and pharmacokinetics results from the phase 1/2 trial of CAT-1004, dubbed MoveDMD trial, in early Q1 2016.

CATB closed Friday's trading at $9.99, up 9.90%.

To represent its innovative culture and heritage as both the pioneer and leader in the RNA-targeted therapeutic space for the past 26 years, Isis Pharmaceuticals Inc. (ISIS) has changed its name to Ionis Pharmaceuticals Inc.

In conjunction with the corporate name change, the company will trade on the NASDAQ Global Select Market under the new ticker symbol "IONS", with effect from December 22, 2015.

ISIS closed Friday's trading at $57.84, down 0.62%. In after hours, the stock was up 0.19% at $57.95.

Minerva Neurosciences Inc. (NERV) has achieved its enrolment target of 234 patients in its ongoing phase IIb trial testing MIN-101 for the treatment of schizophrenia.

The company expects topline results for the core 12-week treatment evaluation period of the trial in the second quarter of 2016.

NERV closed Friday's trading at $5.60, up 4.09%.

Shares of PURE Bioscience Inc. (PURE) were up over 14% on Friday - with the company receiving FDA approval for use of its SDC antimicrobial as poultry processing aid to reduce pathogens, Including Salmonella.

The company expects to begin commercializing PURE Control as a poultry processing aid to reduce Salmonella and other pathogens to prevent foodborne illness by early 2016.

PURE closed Friday's trading at $0.95, up 14.46%.

Shares of Skystar Bio-Pharmaceutical Co. (SKBI) would be suspended from trading on Nasdaq at the open of business on December 21, 2015 because the company failed to comply with Nasdaq's filing requirements.

The company expects to commence trading on the over-the-counter market on December 21, 2015.

SKBI closed Friday's trading at $1.06, down 9.71%.

Threshold Pharmaceuticals Inc. (THLD) is all set to reduce its workforce by approximately two-thirds, resulting in between 20-25 remaining employees, as the company wants to focus its financial resources on the clinical trials of its drug candidate Tarloxotinib.

The one-time severance-related charge associated with the workforce reduction is expected to be about $2.6 million, and majority of the charges will be paid by the end of the first quarter of 2016.

THLD closed Friday's trading at $0.51, down 4.80%. In after hours, the stock was down 10.52% at $0.46.